Delivery Order SPE2DB20D2104-SPE2DB25FMNDY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp on May 30, 2025, for RINVOQ ER 15 mg tablets (30-count units), with final delivery scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (SPE2DX)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $12,446.64 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $24,397.55 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 26, 2025, with an ultimate completion date of June 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,990.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count package) on September 4, 2025, with completion scheduled for September 5, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $3,266.36 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit dose packaging) with a contract value of $36,032.60. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle that extends through...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMNDYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,471.42 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on April 10, 2025, with an ultimate completion date of April 11, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the company's Corporate Office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical supply vendor supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's IDC vehicle enables it to supply a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs globally. This delivery order for RINVOQ (upadacitinib), a rheumatoid arthritis treatment, exemplifies the company's ongoing role as a key supplier within the federal pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 4/10/25 |